Current guidelines for many critical illnesses recommend targeting a MAP of 65 mm Hg, with consideration of higher MAPs in older patients with chronic HTN. Recent literature, however, suggests increased mortality in older patients who are exposed to larger quantities of vasopressor medications. In this podcast, we do a deep dive into the recently published 65 Trial, which sought to evaluate the effect of permissive hypotension in older patients with vasodilatory hypotension.
You can get CME credit for this episode here!Click here for CME Account Creation Instructions
Untreated pain, anxiety, and agitation have both short- and long-term consequences for our critically ill patients. More importantly, it is well-known that patients remember...
[mepr-active rule="1" ifallowed="hide"]Anything in-between gets protected[/mepr-active] hey
In February, we discussed the results of the ADRENAL trial and implications for clinical practice. Since that time, another large trial and meta-analysis has...
